H.Z. Turna

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

Gilberto de Castro, Iveta Kudaba, Yi‐Long Wu et al. · Journal of Clinical Oncology · 2022 · 318 citations · Full text

Medicine, Oncology, Pharmacology +17

LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042

Roy S. Herbst, Gilberto Lopes, Dariusz M. Kowalski et al. · Annals of Oncology · 2019 · 92 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC

Tony Mok, G. Lopes, Byoung Chul Cho et al. · Annals of Oncology · 2023 · 71 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Abstract CT084: Relationship between <i>STK11</i> and <i>KEAP1</i> mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC

Byoung Chul Cho, Gilberto Lopes, Dariusz M. Kowalski et al. · Cancer Research · 2020 · 43 citations

Medicine, Molecular Genetics, Oncology +17